Skip to main content
SpringerLink
Log in

Invariant NKT Cell-Based Vaccine Strategies

  • Chapter
  • First Online:
Natural Killer T cells

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The success of vaccination strategies depends on the efficient generation of appropriate antigen-specific T- and B-cell responses. The unique position of invariant natural killer T (iNKT) cells at the interface of the innate and adaptive immune systems and their ability to direct the maturation of dendritic cells and B cells offers the possibility of harnessing them to “jump-start” the antigen-specific immune response to both microbial pathogen and tumor antigens. In this chapter, we explore the development of pharmacological agents that when used in vaccination strategies as adjuvants to antigenic proteins are able to activate iNKT cells which then augment antigen-specific T- and B-cell responses. In addition, we consider the future directions and challenges in translating these findings from experimental data obtained in mice to use in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Akbari O, Stock P, Meyer EH et al (2008) ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol 180: 5448–5456.

    PubMed  CAS  Google Scholar 

  • Amprey JL, Im JS, Turco SJ et al (2004) A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 200: 895–904.

    Article  PubMed  CAS  Google Scholar 

  • Asano K, Nabeyama A, Miyake Y et al (2011) CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens. Immunity 34: 85–95.

    Article  PubMed  CAS  Google Scholar 

  • Balk SP, Bleicher PA, and Terhorst C (1989) Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci USA 86: 252–256.

    Article  PubMed  CAS  Google Scholar 

  • Barral P, Eckl-Dorna J, Harwood NE et al (2008) B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci USA 105: 8345–8350.

    Article  PubMed  CAS  Google Scholar 

  • Barral P, Polzella P, Bruckbauer A et al (2010) CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 11: 303–312.

    Article  PubMed  CAS  Google Scholar 

  • Batista FD, and Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9: 15–27.

    Article  PubMed  CAS  Google Scholar 

  • Bevan MJ (2006) Cross-priming. Nat Immunol 7: 363–365.

    Article  PubMed  CAS  Google Scholar 

  • Borg NA, Wun KS, Kjer-Nielsen L et al (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448: 44–49.

    Article  PubMed  CAS  Google Scholar 

  • Brigl M, Bry L, Kent SC et al (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4: 1230–1237.

    Article  PubMed  CAS  Google Scholar 

  • Cerundolo V, Silk JD, Masri SH et al (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9: 28–38.

    Article  PubMed  CAS  Google Scholar 

  • Chang DH, Osman K, Connolly J et al (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503–1517.

    Article  PubMed  CAS  Google Scholar 

  • Chang WS, Kim JY, Kim YJ et al (2008) Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 181: 6707–6710.

    PubMed  CAS  Google Scholar 

  • Coquet JM, Chakravarti S, Kyparissoudis K et al (2008) Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 105: 11287–11292.

    Article  PubMed  CAS  Google Scholar 

  • Cox D, Fox L, Tian R et al (2009) Determination of cellular lipids bound to human CD1d molecules. PLoS One 4: e5325.

    Article  PubMed  Google Scholar 

  • Crowe NY, Smyth MJ, and Godfrey DI (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196: 119–127.

    Article  PubMed  CAS  Google Scholar 

  • Cullen R, Germanov E, Shimaoka T et al (2009) Enhanced tumor metastasis in response to ­blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 183: 5807–5815.

    Article  PubMed  CAS  Google Scholar 

  • De Santo C, Arscott R, Booth S et al (2010) Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 11: 1039–1046.

    Article  PubMed  Google Scholar 

  • De Santo C, Salio M, Masri SH et al (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 118: 4036–4048.

    Article  PubMed  Google Scholar 

  • Fischer K, Scotet E, Niemeyer M et al (2004) Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 101: 10685–10690.

    Article  PubMed  CAS  Google Scholar 

  • Fox LM, Cox DG, Lockridge JL et al (2009) Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol 7: e1000228.

    Article  PubMed  Google Scholar 

  • Fujii S, Liu K, Smith C et al (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199: 1607–1618.

    Article  PubMed  CAS  Google Scholar 

  • Fujii S, Shimizu K, Kronenberg M et al (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3: 867–874.

    Article  PubMed  CAS  Google Scholar 

  • Fujii S, Shimizu K, Smith C et al (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198: 267–279.

    Article  PubMed  CAS  Google Scholar 

  • Galli G, Nuti S, Tavarini S et al (2003) CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 197: 1051–1057.

    Article  PubMed  CAS  Google Scholar 

  • Galli G, Pittoni P, Tonti E et al (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104: 3984–3989.

    Article  PubMed  CAS  Google Scholar 

  • Giaccone G, Punt CJ, Ando Y et al (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702–3709.

    PubMed  CAS  Google Scholar 

  • Godfrey DI, Stankovic S, and Baxter AG (2010) Raising the NKT cell family. Nat Immunol 11: 197–206.

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195: 617–624.

    Article  PubMed  CAS  Google Scholar 

  • Guillonneau C, Mintern JD, Hubert FX et al (2009) Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 106: 3330–3335.

    Article  PubMed  CAS  Google Scholar 

  • Halder RC, Aguilera C, Maricic I et al (2007) Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117: 2302–2312.

    Article  PubMed  CAS  Google Scholar 

  • Hammond KJ, Pelikan SB, Crowe NY et al (1999) NKT cells are phenotypically and functionally diverse. Eur J Immunol 29: 3768–3781.

    Article  PubMed  CAS  Google Scholar 

  • Hermans IF, Silk JD, Gileadi U et al (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171: 5140–5147.

    PubMed  CAS  Google Scholar 

  • Ho LP, Denney L, Luhn K et al (2008) Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol 38: 1913–1922.

    Article  PubMed  CAS  Google Scholar 

  • Huang Y, Chen A, Li X et al (2008) Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine 26: 1807–1816.

    Article  PubMed  CAS  Google Scholar 

  • Ishihara S, Nieda M, Kitayama J et al (1999) CD8(+)NKR-P1A (+)T cells preferentially accumulate in human liver. Eur J Immunol 29: 2406–2413.

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa A, Motohashi S, Ishikawa E et al (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910–1917.

    Article  PubMed  CAS  Google Scholar 

  • Jiang X, Shimaoka T, Kojo S et al (2005) Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 175: 2051–2055.

    PubMed  CAS  Google Scholar 

  • Kamijuku H, Nagata Y, Jiang X et al (2008) Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1: 208–218.

    Article  PubMed  CAS  Google Scholar 

  • Kawano T, Cui J, Koezuka Y et al (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626–1629.

    Article  PubMed  CAS  Google Scholar 

  • Kim S, Lalani S, Parekh VV et al (2008) Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J Clin Invest 118: 2301–2315.

    PubMed  CAS  Google Scholar 

  • Kinjo Y, Pei B, Bufali S et al (2008) Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. Chem Biol 15: 654–664.

    Article  PubMed  CAS  Google Scholar 

  • Kinjo Y, Tupin E, Wu D et al (2006) Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7: 978–986.

    Article  PubMed  CAS  Google Scholar 

  • Kinjo Y, Wu D, Kim G et al (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520–525.

    Article  PubMed  CAS  Google Scholar 

  • Ko SY, Ko HJ, Chang WS et al (2005) alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175: 3309–3317.

    PubMed  CAS  Google Scholar 

  • Koch M, Stronge VS, Shepherd D et al (2005) The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 6: 819–826.

    Article  PubMed  CAS  Google Scholar 

  • Kunii N, Horiguchi S, Motohashi S et al (2009) Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 100: 1092–1098.

    Article  PubMed  CAS  Google Scholar 

  • Lanzavecchia A (1985) Antigen-specific interaction between T and B cells. Nature 314: 537–539.

    Article  PubMed  CAS  Google Scholar 

  • Leadbetter EA, Brigl M, Illarionov P et al (2008) NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci USA 105: 8339–8344.

    Article  PubMed  CAS  Google Scholar 

  • Lee WY, Moriarty TJ, Wong CH et al (2010) An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 11: 295–302.

    Article  PubMed  CAS  Google Scholar 

  • Li X, Fujio M, Imamura M et al (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 107: 13010–13015.

    Article  PubMed  CAS  Google Scholar 

  • Liu K, Idoyaga J, Charalambous A et al (2005) Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202: 1507–1516.

    Article  PubMed  CAS  Google Scholar 

  • Macdonald HR (2007) NKT cells: In the beginning. Eur J Immunol 37 Suppl 1: S111-115.

    Article  PubMed  CAS  Google Scholar 

  • Mallevaey T, Scott-Browne JP, Matsuda JL et al (2009) T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity 31: 60–71.

    Article  PubMed  CAS  Google Scholar 

  • Matsuda JL, Gapin L, Baron JL et al (2003) Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 100: 8395–8400.

    Article  PubMed  CAS  Google Scholar 

  • Matsuda JL, Mallevaey T, Scott-Browne J et al (2008) CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Curr Opin Immunol 20: 358–368.

    Article  PubMed  CAS  Google Scholar 

  • Mattner J, Debord KL, Ismail N et al (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525–529.

    Article  PubMed  CAS  Google Scholar 

  • Mattner J, Savage PB, Leung P et al (2008) Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3: 304–315.

    Article  PubMed  CAS  Google Scholar 

  • McCarthy C, Shepherd D, Fleire S et al (2007) The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 204: 1131–1144.

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto K, Miyake S, and Yamamura T (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531–534.

    Article  PubMed  CAS  Google Scholar 

  • Morita M, Motoki K, Akimoto K et al (1995) Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38: 2176–2187.

    Article  PubMed  CAS  Google Scholar 

  • Motohashi S, Nagato K, Kunii N et al (2009) A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492–2501.

    Article  PubMed  CAS  Google Scholar 

  • Nagarajan NA, and Kronenberg M (2007) Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 178: 2706–2713.

    PubMed  CAS  Google Scholar 

  • Nieda M, Okai M, Tazbirkova A et al (2004) Therapeutic activation of Valpha24  +  Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383–389.

    Article  PubMed  CAS  Google Scholar 

  • O’Konek JJ, Illarionov P, Khursigara DS et al (2011) Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity. J Clin Invest 121: 683–694.

    Article  PubMed  Google Scholar 

  • Paget C, Mallevaey T, Speak AO et al (2007) Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27: 597–609.

    Article  PubMed  CAS  Google Scholar 

  • Parekh VV, Wilson MT, Olivares-Villagomez D et al (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115: 2572–2583.

    Article  PubMed  CAS  Google Scholar 

  • Pellicci DG, Patel O, Kjer-Nielsen L et al (2009) Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 31: 47–59.

    Article  PubMed  CAS  Google Scholar 

  • Petersen TR, Sika-Paotonu D, Knight DA et al (2010) Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol 88: 596–604.

    Article  PubMed  CAS  Google Scholar 

  • Reddy BG, Silk JD, Salio M et al (2009) Nonglycosidic agonists of invariant NKT cells for use as vaccine adjuvants. ChemMedChem 4: 171–175.

    Article  PubMed  CAS  Google Scholar 

  • Sada-Ovalle I, Chiba A, Gonzales A et al (2008) Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 4: e1000239.

    Article  PubMed  Google Scholar 

  • Salio M, and Cerundolo V (2009) Linking inflammation to natural killer T cell activation. PLoS Biol 7: e1000226.

    Article  PubMed  Google Scholar 

  • Salio M, Speak AO, Shepherd D et al (2007) Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci USA 104: 20490–20495.

    Article  PubMed  CAS  Google Scholar 

  • Savage PB, Teyton L, and Bendelac A (2006) Glycolipids for natural killer T cells. Chem Soc Rev 35: 771–779.

    Article  PubMed  CAS  Google Scholar 

  • Scott-Browne JP, Matsuda JL, Mallevaey T et al (2007) Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol 8: 1105–1113.

    Article  PubMed  CAS  Google Scholar 

  • Semmling V, Lukacs-Kornek V, Thaiss CA et al (2010) Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 11: 313–320.

    Article  PubMed  CAS  Google Scholar 

  • Shimizu K, Goto A, Fukui M et al (2007a) Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178: 2853–2861.

    PubMed  CAS  Google Scholar 

  • Shimizu K, Kurosawa Y, Taniguchi M et al (2007b) Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204: 2641–2653.

    Article  PubMed  CAS  Google Scholar 

  • Silk JD, Hermans IF, Gileadi U et al (2004) Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114: 1800–1811.

    PubMed  CAS  Google Scholar 

  • Silk JD, Salio M, Reddy BG et al (2008) Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 180: 6452–6456.

    PubMed  CAS  Google Scholar 

  • Smyth MJ, Thia KY, Street SE et al (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191: 661–668.

    Article  PubMed  CAS  Google Scholar 

  • Stober D, Jomantaite I, Schirmbeck R et al (2003) NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 170: 2540–2548.

    PubMed  CAS  Google Scholar 

  • Taraban VY, Martin S, Attfield KE et al (2008) Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol 180: 4615–4620.

    PubMed  CAS  Google Scholar 

  • Tonti E, Galli G, Malzone C et al (2009) NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood 113: 370–376.

    Article  PubMed  CAS  Google Scholar 

  • Uchida T, Horiguchi S, Tanaka Y et al (2008) Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57: 337–345.

    Article  PubMed  CAS  Google Scholar 

  • Uldrich AP, Crowe NY, Kyparissoudis K et al (2005) NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175: 3092–3101.

    PubMed  CAS  Google Scholar 

  • Vincent MS, Leslie DS, Gumperz JE et al (2002) CD1-dependent dendritic cell instruction. Nat Immunol 3: 1163–1168.

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Cheng L, Wondimu Z et al (2009) Cutting edge: CD28 engagement releases antigen-activated invariant NKT cells from the inhibitory effects of PD-1. J Immunol 182: 6644–6647.

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Li Y, Kinjo Y et al (2010) Lipid binding orientation within CD1d affects recognition of Borrelia burgorferi antigens by NKT cells. Proc Natl Acad Sci USA 107: 1535–1540.

    Article  PubMed  CAS  Google Scholar 

  • Youn HJ, Ko SY, Lee KA et al (2007) A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25: 5189–5198.

    Article  PubMed  CAS  Google Scholar 

  • Yuan W, Kang SJ, Evans JE et al (2009) Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. J Immunol 182: 4784–4791.

    Article  PubMed  CAS  Google Scholar 

  • Zaini J, Andarini S, Tahara M et al (2007) OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 117: 3330–3338.

    Article  PubMed  CAS  Google Scholar 

  • Zajonc DM, Cantu C, 3 rd, Mattner J et al (2005) Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 6: 810–818.

    Google Scholar 

  • Zeng Z, Castano AR, Segelke BW et al (1997) Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 277: 339–345.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Moira Johnson for editorial advice and assistance. J.-P. J. is supported by a program grant from The Wellcome Trust. J.S. and M.S. are supported by CRUK (program grant and ECMC stream). Research in the Human Immunology Unit is supported by the Medical Research Council.

Author information

Authors and Affiliations

  1. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

    John-Paul Jukes, Jonathan D. Silk & Mariolina Salio

  2. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 9DU, UK

    Vincenzo Cerundolo

Authors
  1. John-Paul Jukes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan D. Silk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariolina Salio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincenzo Cerundolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Cerundolo .

Editor information

Editors and Affiliations

  1. National Cancer Institute (NCI), Molecular Immunogenetics & Vaccine, National Institutes of Health (NIH), Center Drive 10, Bethesda, 20892-1578, Maryland, USA

    Masaki Terabe

  2. National Cancer Institute, Lab. Developmental &, National Institutes of Health (NIH), Bethesda, 20892, Maryland, USA

    Jay A. Berzofsky

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jukes, JP., Silk, J.D., Salio, M., Cerundolo, V. (2012). Invariant NKT Cell-Based Vaccine Strategies. In: Terabe, M., Berzofsky, J. (eds) Natural Killer T cells. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0613-6_3

Download citation

Publish with us

Policies and ethics

Search

Navigation